REGENXBIO Inc. (RGNX) has made remarkable progress in being able to advance its pipeline with various types of gene therapies. The last time I wrote about this article it was in a Seeking Alpha ...
Zacks Investment Research on MSN
KROS stock: What to know about Rinvatercept in DMD
Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks Consensus Estimate of a loss of 15 cents. Earnings rose 99% year over year, ...
Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.
CEO Jasbir Seehra outlined the company’s development priorities and partnership plans during a presentation at Oppenheimer’s ...
Sarepta Therapeutics says its RNA therapy for Duchenne muscular dystrophy (DMD) could be more effective than its existing drugs, but a dose-escalation study also dug up some new—and serious—adverse ...
– DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026 – BOSTON--(BUSINESS WIRE)-- PepGen Inc. (PEPG), a clinical-stage ...
Tufts University is now offering a combined Doctor of Dental Medicine/Master of Public Health (DMD/MPH) degree offered through Tufts University School of Dental Medicine and Tufts University School of ...
The University of Southern Nevada (USN) plans to expand its College of Dental Medicine by implementing a doctor of dental medicine (DMD) program at the university’s campus in South Jordan, UT. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results